



Newsletter

INDIAN PHARMACOPOEIA COMMISSION

MINISTRY OF HEALTH & FAMILY WELFARE, GOVT. OF INDIA

VOL 2 | 2025



Empowering Public Health by
Promoting Quality of Medicines and Patient Safety

CONTENTS

1. Message from the Secretary-cum-Scientific Director.....	1
2. Indian Pharmacopoeia 2026 – Salient Features.....	2
3. Global Recognitions of the IP.....	18
4. IP Reference Standards.....	21
5. National Collaborations.....	22
6. International Engagements	24
7. Interactive Meets, Conferences & Training Activities.....	28
8. Significant Activities.....	36
8. Webinars by the Indian Pharmacopoeia Commission.....	38



Editorial Team

Dr. Gaurav Pratap Singh Jadaun - *Editor*
Senior Principal Scientific Officer

Ms. Ayshu Bhardwaj - *Associate Editor*
Pharmacopoeia Editor

Dr. Shruti Rastogi - *Associate Editor*
Scientific Assistant

Mr. Saurabh Sahoo - *Associate Editor*
Pharmacopoeia Proof Reader



From the Secretary-cum-Scientific Director's Desk

It gives me immense pleasure to present Volume 2 (2025) of the IPC Newsletter, which captures a year of sustained progress, strategic partnerships, and collective efforts towards strengthening India's drug quality and patient safety ecosystem. The breadth of activities highlighted in this issue reflects IPC's expanding national and international footprint, guided by scientific rigor, regulatory excellence, and public health priorities.

During the year, the Indian Pharmacopoeia (IP) continued to gain significant global recognition, with new MoUs signed with Trinidad and Tobago, Maldives, Botswana, and Liberia, marking important milestones in pharmacopoeial cooperation and international trust in India's quality standards. Parallely, IPC strengthened domestic collaborations with State Pharmacy Councils and regulatory authorities, reinforcing rational use of medicines, pharmacovigilance, materiovigilance, and wider adoption of the National Formulary of India at the grassroots level.

IPC's active engagement in international regulatory forums, scientific conferences, hands-on trainings, workshops, and interactive meets demonstrates our commitment to capacity building, harmonisation, and knowledge exchange. The development of new Indian Pharmacopoeia Reference Standards, enhanced analytical capabilities for DEG/EG testing, and focused initiatives in critical areas such as blood safety, tuberculosis, and non-animal testing methods further underline IPC's role as a science-driven institution.

Equally important are our people-centric initiatives including participation in the Rashtriya Karmayogiprogramme, observance of Swasth Nari Sashakt Parivar Abhiyaan, and promotion of Hindi through Hindi Pakhwada which reflect IPC's alignment with national missions and values-driven governance.

I extend my sincere appreciation to all our stakeholders, collaborators, scientists, and staff members whose dedication and professionalism continue to propel IPC forward. Together, we remain committed to advancing medicine quality standards, strengthening regulatory systems, and contributing meaningfully to national and global public health.

Dr. Vivekanandan Kalaiselvan
Secretary-cum-Scientific Director
Indian Pharmacopoeia Commission

Indian Pharmacopoeia 2026

Salient Features

New Monographs: 121

- Drug substances, Dosage forms and Pharmaceutical aids (A to Z),: 88
- Vitamins, Minerals, Amino Acids, Fatty Acids etc.: 05
- Vaccines and Immunoserum for human use: 03
- Blood Related Products: 02
- Biotechnology Derived Therapeutic products: 02
- Blood and Blood components: 20
- Veterinary vaccines: 01

New Monograph Additions (N= 121)

Chemicals (N= 88)

1. Acamprosate Gastro-resistant Tablets
2. Acetylcysteine
3. Acetylcysteine Injection
4. Adapalene
5. Adapalene Gel
6. Adenine
7. Aluminium Sulphate
8. Amantadine Tablets
9. Azilsartan and Chlorthalidone Tablets
10. Bedaquiline Fumarate
11. Bedaquiline Tablets
12. Bepotastine Besylate
13. Bepotastine Besylate Ophthalmic Solution
14. Bepotastine Tablets
15. Bilastine and Montelukast Tablets
16. Caffeine Citrate Injection
17. Calcium Orotate
18. Calcium Polystyrene Sulphonate
19. Carbamazepine Oral Suspension
20. Cefprozil
21. Cefprozil Tablets
22. Cefuroxime Axetil for Oral Suspension
23. Celecoxib Capsules
24. Ciprofloxacin Eye Ointment
25. Ciprofloxacin for Oral Suspension
26. Clarithromycin for Oral Suspension
27. Clarithromycin Prolonged-release Tablets
28. Clindamycin Gel
29. Clindamycin Lotion
30. Copper Sulphate
31. Daclatasvir Tablets
32. Dactinomycin
33. Dactinomycin for Injection
34. Dapagliflozin
35. Dapagliflozin and Metformin Hydrochloride Prolonged-release Tablets
36. Dapagliflozin Propanediol Monohydrate
37. Dapagliflozin Tablets
38. 3-O-desacyl-4'-monophosphoryl lipid A
39. Desloratadine
40. Desloratadine Tablets
41. Diazepam Oral Solution
42. Diltiazem Prolonged-release Capsules
43. Edetate Calcium Disodium
44. Entecavir Oral Solution
45. Eribulin Mesylate
46. Eribulin Injection
47. Etravirine
48. Etravirine Tablets
49. Ferric Carboxymaltose
50. Fexofenadine and Montelukast Tablets

- | | |
|---|--|
| 51. Frusemide Oral Solution | 71. Paracetamol Suppositories |
| 52. Fulvestrant Injection | 72. Paracetamol and Mefenamic Acid Suspension |
| 53. Galantamine Tablets | 73. Paracetamol and Mefenamic Acid Tablets |
| 54. Haemodialysis Solutions | 74. Pilocarpine Hydrochloride |
| 55. Hydrocortisone Tablets | 75. Pilocarpine Hydrochloride Eye Drops |
| 56. Low substituted Hydroxypropyl Cellulose | 76. Pomalidomide |
| 57. Iohexol | 77. Pomalidomide Capsules |
| 58. Iohexol Injection | 78. Proparacaine Hydrochloride |
| 59. Itraconazole Oral Solution | 79. Proparacaine Eye Drops |
| 60. Ketoconazole Shampoo | 80. Sildenafil Injection |
| 61. Levetiracetam Injection | 81. Sodium Polystyrene Sulphonate |
| 62. Mefenamic Acid Tablets | 82. Sodium Stearyl Fumarate |
| 63. Micafungin Sodium | 83. Tramadol Injection |
| 64. Micafungin for Injection | 84. Tramadol Tablets |
| 65. Minocycline Hydrochloride | 85. Tricholine Citrate |
| 66. Minocycline Capsules | 86. Vildagliptin and Metformin Prolonged-release Tablets |
| 67. Minocycline for Injection | 87. Xylitol |
| 68. Minocycline Tablets | 88. Zinc Gluconate |
| 69. Morphine Prolonged-release Tablets | |
| 70. Oxytocin Concentrated Solution | |

Vitamins, Minerals, Amino acids, Fatty Acids etc. (N= 05)

1. Calcium Folate Tablets
2. Ferric Carboxymaltose injection
3. Phytomenadione Tablets
4. Potassium Iodide Tablets
5. Zinc Gluconate Tablets

Vaccines and Immunoserum for Human Use (N= 03)

1. Human Papillomavirus Vaccine (rDNA)
2. Meningococcal Group A, C, W135, Y and X Conjugate Vaccine
3. Diphtheria, Tetanus and acellular Pertussis vaccine (Adsorbed, reduced diphtheria and acellular pertussis antigen content): dTaP for adults and adolescents

Blood Related Products (N= 02)

1. Human Fibrinogen (Dried)
2. Hepatitis B Immunoglobulin for Intravenous Use

Blood and Blood Components (N= 20)

Whole Blood

1. Whole Blood, Irradiated

Red Cell Components

1. Red Blood Cell, in Additive Solution
2. Leucodepleted Red Blood Cells
3. Red Blood Cells, Buffy Coat Removed, in Additive Solution
4. Red Blood Cells, Cryopreserved
5. Red Blood Cells Washed

Plasma Components

1. Fresh Frozen Plasma (FFP), Whole Blood
2. Fresh Frozen Plasma (FFP), Apheresis method
3. Cryoprecipitate
4. Cryo-poor Plasma (CPP)

Granulocyte Components

1. Granulocytes Apheresis method
2. Pooled Granulocytes Buffy Coat metho

Platelets Components

1. Platelet Rich Plasma (PRP)
2. Pooled Random Donor Platelets
3. Pooled Platelets Concentrate, Buffy Coat method
4. Random donor Platelet Concentrate, PRP method
5. Random donor Platelet Concentrate, Buffy coat method
6. Single Donor Platelets (SDP), Apheresis method
7. Single Donor Platelets in Additive Solution (SDP-PAS)
8. Double Single Donor Platelets, Apheresis method

Biotechnology Derived Therapeutic Products (N= 02)

1. Trastuzumab Concentrated solution

Veterinary Vaccines (N= 01)

1. Infectious Bovine Rhinotracheitis (IBR) Vaccine, Inactivated

New General Chapters Additions

New General Chapters

- 1.2.34 Disinfectants and Antiseptics
- 1.2.35 Detection of Viral Extraneous Agents Using High Throughput Sequencing (HTS)
- 2.4.48 Powder Flow
- 2.4.49 Powder Fineness
- 1.4.50 Chromatographic Separation Technique

New General Monographs

Liquids for Cutaneous Application

New General Requirements

Blood and Blood Components

General Requirements: Blood and Blood Components from Human Source

General Requirements: Irradiation of Blood and Blood Components

Upgradations

General Notices

General chapters

- | | | | |
|--------|---|--------|--|
| 2.1.7 | Balances used in Analytical Procedures | 2.2.2 | Effectiveness of Antimicrobial Preservatives |
| 2.2.3 | Bacterial Endotoxins | 2.3.6 | Related Foreign Steroids |
| 2.3.18 | Sulphated Ash | 2.3.30 | Nitrogen |
| 2.3.42 | Assay of Vitamin D | 2.3.43 | Water |
| 2.3.46 | Assay of Insulins | 2.3.48 | Thiomersal |
| 2.3.49 | Protein | 2.3.50 | Fatty Acid Composition by Gas Chromatography |
| 2.3.52 | Assay of Folic Acid | 2.4.1 | Appearance of Solution |
| 2.4.9 | Conductivity | 2.4.13 | Gas Chromatography |
| 2.4.14 | Liquid Chromatography | 2.4.15 | Paper Chromatography |
| 2.4.16 | Size-Exclusion Chromatography | 2.4.17 | Thin-Layer Chromatography |
| 2.4.24 | pH Values | 2.4.26 | Solubility |
| 2.4.30 | Total Organic Carbon in Water | 2.4.32 | Capillary Electrophoresis |
| 2.4.35 | Bulk density and tapped density of Powder | 2.5.1 | Disintegration. |

- | | | | |
|-------|--|-------|--|
| 2.5.2 | Dissolution | 2.5.3 | Weight Variation |
| 2.5.4 | Uniformity of Dosage Unit | 2.7.2 | Cell Substrates for the Production of Vaccines for Human Use |
| 2.7.3 | Test for Extraneous Agents in Viral Vaccines for Human Use | 4.1 | Buffer Solutions |
| 4.2 | General Reagents | 4.5. | Volumetric Reagents and Solutions |
| 5.4 | Residual Solvents | 5.10 | Elemental Impurities |
| 6.2 | Containers | | |

General Monographs

- | | | | |
|----|-------------------------|----|-------------------------|
| 1. | Capsules | 2. | Granules |
| 3. | Inhalation Preparations | 4. | Liposomal Preparations |
| 5. | Nasal Preparations | 6. | Ointments |
| 7. | Oral Liquids | 8. | Parenteral Preparations |
| 9. | Tablets | | |

Monographs

Drug substances, Dosage forms and Pharmaceutical aids

- | | | | |
|-----|-------------------------------|-----|---|
| 1. | Acarbose | 16. | Aminophylline Prolonged-release Tablets |
| 2. | Acarbose Tablets | 17. | Aminophylline Tablets |
| 3. | Acamprosate Calcium | 18. | Amlodipine and Nebivolol Tablets |
| 4. | Aceclofenac | 19. | Amlodipine and Olmesartan Medoxomil Tablets |
| 5. | Acesulphame Potassium | 20. | Amorolfine Hydrochloride |
| 6. | Aciclovir | 21. | Amoxicillin Sodium |
| 7. | Aciclovir Cream | 22. | Amoxicillin and Potassium Clavulanate Injection |
| 8. | Aciclovir Dispersible Tablets | 23. | Amoxicillin and Potassium Clavulanate Oral Suspension |
| 9. | Aciclovir Eye Ointment | 24. | Amoxicillin and Potassium Clavulanate Tablets |
| 10. | Aciclovir Infusion | 25. | Amphotericin B |
| 11. | Aciclovir Oral Suspension | 26. | Anastrozole Tablets |
| 12. | Aciclovir Tablets | 27. | Aprepitant |
| 13. | Albendazole Tablets | 28. | Aripiprazole |
| 14. | Aminophylline | 29. | Aripiprazole Tablets |
| 15. | Aminophylline Injection | 30. | Atazanavir Sulphate |

- | | |
|--|---|
| 31. Atenolol | 61. Carboxymethylcellulose Eye Drops |
| 32. Atorvastatin Calcium | 62. Carvedilol |
| 33. Atorvastatin Tablets | 63. Carvedilol Tablets |
| 34. Atracurium Besylate | 64. Cefepime Hydrochloride |
| 35. Atropine Sulphate | 65. Cefepime Injection |
| 36. Bacitracin Zinc | 66. Cefixime Tablets |
| 37. Beclomethasone Dipropionate | 67. Cefotaxime Sodium |
| 38. Bendamustine Hydrochloride | 68. Ceftriaxone Sodium |
| 39. Bendamustine for Injection | 69. Ceftriaxone Injection |
| 40. Benzhexol Hydrochloride | 70. Cefuroxime Axetil Tablets |
| 41. Benzhexol Tablets | 71. Cefuroxime Sodium |
| 42. Benzyl Alcohol | 72. Cefuroxime Injection |
| 43. Benzyl Benzoate Application | 73. Cetostearyl Alcohol |
| 44. Betahistine Tablets | 74. Cetyl Alcohol |
| 45. Betamethasone Valerate Cream | 75. Chloramphenicol Ear Drops |
| 46. Betamethasone Valerate Ointment | 76. Chlorhexidine Acetate |
| 47. Bisacodyl Gastro-resistant Tablets | 77. Chlorhexidine Gluconate Solution |
| 48. Budesonide | 78. Chlorhexidine Hydrochloride |
| 49. Bosutinib | 79. Chlorhexidine Mouthwash |
| 50. Butylated Hydroxytoluene | 80. Chlorpheniramine Maleate |
| 51. Caffeine | 81. Cilostazol Tablets |
| 52. Caffeine Citrate Oral Solution | 82. Ciprofloxacin |
| 53. Aqueous Calamine Cream | 83. Ciprofloxacin Injection |
| 54. Calamine Ointment | 84. Ciprofloxacin Hydrochloride |
| 55. Capreomycin Injection | 85. Ciprofloxacin Eye Drops |
| 56. Carbamazepine | 86. Ciprofloxacin Tablets |
| 57. Carbamazepine Tablet | 87. Cisplatin Injection |
| 58. Carbidopa and Levodopa Orally Disintegrating Tablets | 88. Cisplatin for Injection |
| 59. Carboplatin | 89. Clarithromycin |
| 60. Carboprost Tromethamine | 90. Clindamycin Palmitate Hydrochloride Oral Suspension |

- | | |
|--|---|
| 91. Clindamycin Phosphate | 121. Dithranol Ointment |
| 92. Clindamycin Injection | 122. Docetaxel Anhydrous |
| 93. Clobetasol Propionate | 123. Docetaxel Trihydrate |
| 94. Clobetasol Cream | 124. Docusate Tablets |
| 95. Clobetasol Ointment | 125. Dolutegravir Tablets |
| 96. Clomifene Citrate | 126. Doxepin Hydrochloride |
| 97. Clomifene Tablets | 127. Doxepin Capsules |
| 98. Clonazepam | 128. Duloxetine Hydrochloride |
| 99. Clonazepam Injection | 129. Dutasteride |
| 100. Clonazepam Tablets | 130. Enoxaparin Sodium |
| 101. Clonidine Hydrochloride | 131. Entecavir |
| 102. Clopidogrel and Aspirin
Tablets | Escitalopram Oxalate |
| 103. Clotrimazole | 133. Esomeprazole Magnesium Trihydrate |
| 104. Clotrimazole Lotion | 134. Esomeprazole Gastro-resistant Capsules |
| 105. Colistimethate Sodium | 135. Esomeprazole Gastro-resistant Tablets |
| 106. Colistimethate for Injection | 136. Ethanolamine |
| 107. Colistin Sulphate | 137. Anaesthetic Ether |
| 108. Colistin Tablets | 138. Ethinyloestradiol Tablets |
| 109. Copovidone | 139. Ethosuximide Capsules |
| 110. Cyclobenzaprine Tablets | 140. Fenofibrate Capsules |
| 111. Cyproheptadine
Hydrochloride | 141. Finasteride |
| 112. Cyproheptadine Syrup | 142. Fluconazole |
| 113. Cyproheptadine Tablets | 143. Fluconazole Capsules |
| 114. Dextromethorphan
Hydrobromide | 144. Fluconazole Oral Suspension |
| 115. Dibasic Calcium Phosphate,
Anhydrous | 145. Fluconazole Tablets |
| 116. Dibasic Calcium Phosphate,
Dihydrate | 146. Fluocinolone Acetonide |
| 117. Dicyclomine Hydrochloride | 147. Fluphenazine Decanoate |
| 118. Dicyclomine Injection | 148. Frusemide |
| 119. Dicyclomine Oral Solution | 149. Frusemide Injection |
| 120. Dicyclomine Tablets | 150. Frusemide Tablets |

- | | |
|---|---|
| 151. Gelatin | 181. Mercaptopurine |
| 152. Gemifloxacin Tablets | 182. Mesalazine |
| 153. Glimepiride | 183. Mesalazine Prolonged-release Tablets |
| 154. Glipizide | 184. Metformin Hydrochloride |
| 155. Glyceryl Trinitrate Sublingual Tablets | 185. Metformin Oral Solution |
| 156. Homatropine Methylbromide | 186. Metformin Hydrochloride Prolonged-release Tablets |
| 157. Hydrochlorothiazide | 187. Metformin Tablets |
| 158. Hydroxyprogesterone Hexanoate | 188. Methadone Tablets |
| 159. Hyoscine Butylbromide Injection | 189. Methotrexate |
| 160. Hyoscine Butylbromide Tablets | 190. Methotrexate Injection |
| 161. Imipramine Tablets | 191. Methotrexate Tablets |
| 162. Isoprenaline Sulphate | 192. Methylprednisolone Tablets |
| 163. Isopropyl Alcohol | 193. Metolazone |
| 164. Ketorolac Tromethamine | 194. Metolazone Tablets |
| 165. Ketorolac Tromethamine Injection | 195. Mitiglinide Calcium Dihydrate |
| 166. Ketorolac Tromethamine Tablets | 196. Mometasone Furoate |
| 167. Levodopa and Carbidopa Tablets | 197. Mometasone Aqueous Nasal Spray |
| 168. Levofloxacin Injection | 198. Mometasone Cream |
| 169. Levosalbutamol Hydrochloride | 199. Mometasone Ointment |
| 170. Levosalbutamol Sulphate | 200. Montelukast Sodium |
| 171. Linezolid | 201. Montelukast Tablets |
| 172. Linezolid Tablets | 202. Morphine Injection |
| 173. Loperamide Hydrochloride | 203. Multiple Electrolytes and Dextrose Injection Type I |
| 174. Loratadine Tablets | 204. Multiple Electrolytes and Dextrose Injection Type II |
| 175. Lorazepam | 205. Multiple Electrolytes and Dextrose Injection Type V |
| 176. Luliconazole | 206. Multiple Electrolytes Injection Type VI |
| 177. Magnesium Stearate | 207. Naltrexone Hydrochloride |
| 178. Mannitol | 208. Nicotinic Acid |
| 179. Meclizine Hydrochloride | 209. Norfloxacin |
| 180. Menthol | 210. Norfloxacin Tablets |

- | | |
|--|--|
| 211. Oleic Acid | 241. Phenytoin Tablets |
| 212. Olmesartan Medoxomil and Hydrochlorothiazide Tablets | 242. Pioglitazone Hydrochloride |
| 213. Olopatadine Ophthalmic Solution | 243. Piroxicam |
| 214. Omeprazole | 244. Pitavastatin Calcium |
| 215. Omeprazole Gastro-resistant Capsules | 245. Prazosin Hydrochloride |
| 216. Ondansetron | 246. Prazosin Tablets |
| 217. Ondansetron Hydrochloride | 247. Prednisolone |
| 218. Ondansetron Injection | 248. Prednisolone Acetate |
| 219. Ondansetron Tablets | 249. Prednisone Tablets |
| 220. Ornidazole | 250. Prochlorperazine Maleate |
| 221. Orphenadrine Hydrochloride | 251. Progesterone |
| 222. Oxcarbazepine | 252. Progesterone Injection |
| 223. Oxcarbazepine Tablets | 253. Promethazine Hydrochloride |
| 224. Oxybutynin Tablets | 254. Promethazine Injection |
| 225. Oxytocin | 255. Promethazine Syrup |
| 226. Oxytocin Injection | 256. Promethazine Tablets |
| 227. Pantoprazole Sodium | 257. Propranolol Hydrochloride |
| 228. Pantoprazole Gastro-resistant and Domperidone Prolonged | 258. Propranolol Prolonged-release Capsules |
| 229 release Capsules | 259. Propranolol Injection |
| 230 Parecoxib Sodium | 260. Propranolol Tablets |
| 231 Paroxetine Prolonged-release Tablets | 261. Propyl Gallate |
| 232 Phenindione | 262. Pyrazinamide Tablets |
| 233 Phenindione Tablets | 263. Quinapril and Hydrochlorothiazide Tablets |
| 234 Phenylephrine Hydrochloride | 264. Quinidine Sulphate |
| 235 Phenylephrine Eye Drops | 265. Quinine Bisulphate Tablets |
| 236 Phenylephrine Injection | 266. Quinine Dihydrochloride Injection |
| 237 Phenytoin | 267. Quinine Sulphate |
| 238 Phenytoin Sodium | 268. Quinine Tablets |
| 239 Phenytoin Capsules | 269. Ramipril |
| 240 Phenytoin Oral Suspension | 270. Ramipril Capsules |

- | | |
|--|---|
| 271. Ramipril Tablets | 296. Theophylline Injection |
| 272. Ropinirole Prolonged-release Tablets | 297. Theophylline Prolonged-release Tablets |
| 273. Ropinirole Tablets | 298. Tobramycin Sulphate |
| 274. Rosuvastatin Calcium | 299. Tolnaftate |
| 275. Rosuvastatin Tablets | 300. Topiramate |
| 276. Rupatadine Fumarate | 301. Topotecan Injection |
| 277. Salbutamol | 302. Tramadol Capsules |
| 278. Salbutamol Sulphate | 303. Tranexamic Acid |
| 279. Salbutamol Injection | 304. Travoprost Eye Drops |
| 280. Sertraline Tablets | 305. Triamcinolone Acetonide |
| 281. Sildenafil Citrate | 306. Triamcinolone Acetonide Injection |
| 282. Simvastatin | 307. Trimetazidine Hydrochloride |
| 283. Simvastatin Tablets | 308. Trimethoprim and Sulphamethoxazole Oral Suspension |
| 284. Sitagliptin Tablets | 309. Trimethoprim and Sulphamethoxazole Tablets |
| 285. Sodium Phosphate | 310. Tubocurarine Chloride |
| 286. Sulphacetamide Sodium | 311. Ursodeoxycholic Acid |
| 287. Sulphacetamide Eye Drops | 312. Ursodeoxycholic Acid Tablets |
| 288. Sulphamethoxazole | 313. Valacyclovir Tablets |
| 289. Telmisartan Tablets | 314. Vancomycin Hydrochloride |
| 290. Tamsulosin Hydrochloride | 315. Vancomycin Capsules |
| 291. Tapentadol Hydrochloride | 316. Purified Water |
| 292. Temozolomide Capsules | 317. Water for Injections |
| 293. Tenofovir Disoproxil Fumarate | 318. Sterile Water for Inhalation |
| 294. Tenofovir Disoproxil Fumarate Tablets | 319. Sterile Water for Injections |
| 295. Theophylline | |

Vitamins, Minerals, Amino Acids, Fatty Acids Etc.

1. Calcium Folate Injection

Herbs and Herbal Product

1. Arachis Oil
2. Coconut Oil
3. Sarpagandha Tablets
4. Clove Oil
5. Rosemary Oil
6. Senna Tablets

Vaccines and Immunoserum for Human Use

1. Adsorbed Pertussis Vaccine (Acellular Component)
2. Diphtheria and Tetanus Vaccine (Adsorbed) for Adults and
3. Adolescents
4. Influenza Vaccine (Human, Live Attenuated)
5. Pertussis Vaccine (Whole Cell)
6. Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)
7. Tetanus Vaccine (Adsorbed)
8. Typhoid Vi Conjugate Vaccine

Blood and Blood Related Products

1. Anti-D (IgM) Monoclonal Blood Grouping Reagent
2. Anti-D Blend (IgM +IgG) Monoclonal Reagent
3. Anti-Human Globulin (AHG) Serum
4. Antithrombin III Concentrate
5. Fibrin sealant Kit
6. Human Albumin
7. Human coagulation factor VIII (rDNA)
8. Human coagulation factor IX
9. Human Normal Immunoglobulin
10. Human Normal Immunoglobulin for Intravenous use
11. Human Plasma Protein Fraction
12. Human Prothrombin Complex
13. Packed Red Blood Cells
14. Whole Blood

Biotechnology Derived Therapeutic Products

1. Erythropoietin injection
2. Follicle Stimulating Hormone Injection
3. Rituximab
4. Rituximab Injection
5. Teriparatide
6. Teriparatide Injection

Veterinary Monographs

1. Intramammary Infusions
2. Intrauterine Preparations
3. Veterinary Liquid Preparations for Cutaneous Application
4. Veterinary Oral Liquids
5. Veterinary Oral Pastes
6. Veterinary Oral Powders
7. Amitraz Dip Concentrate Liquid
8. Amitraz Dip Concentrate Powder
9. Amitraz Pour-on
10. Ampicillin Veterinary Oral Powder
11. Cefoperazone Sodium Intramammary Suspension
12. Cefuroxime Intramammary Infusion
13. Deltamethrin Pour-on
14. Dichlorophen Veterinary Aerosol
15. Inositol
16. Ivermectin Pour-on
17. Meclofenamic Acid
18. Meloxicam Injection

Veterinary Vaccines

1. Anthrax Spore Vaccine, Live
2. Avian Infectious Bronchitis Vaccine, Inactivated
3. Avian Spirochaetosis Vaccine, inactivated
4. Avian Infectious Bronchitis Vaccine, Live
5. Avian Infectious Laryngotracheitis Vaccine, Live
6. Brucella Abortus (Strain 19 Vaccine) Vaccine, Live
7. Blackquarter Vaccine, inactivated
8. Bluetongue Vaccine, Inactivated
9. Canine Distemper Vaccine, Live
10. Canine Adenovirus Vaccine, Live
11. Canine Coronavirus Vaccine, Inactivated
12. Canine Parvovirus Vaccine, Inactivated
13. Canine leptospirosis Vaccine, Inactivated
14. Canine Parainfluenza Virus Vaccine, Live
15. Duck Pasteurella Vaccine, Inactivated
16. Canine Parvovirus Vaccine, Live
17. Classical Swine Fever Vaccine, Live
18. Enterotoxaemia Vaccine, Inactivated
19. Duck Plague Vaccine, Live
20. Egg Drop Syndrome'76 Vaccine, Inactivated
21. Fowl Pox Vaccine, Live
22. Foot-and-Mouth Disease Vaccine, Inactivated
23. Fowl Cholera Vaccine, Inactivated
24. Inclusion Body Hepatitis (IBH) Vaccine, inactivated
25. Goat Pox Vaccine, Live
26. Haemorrhagic Septicaemia Vaccine, Inactivated
27. Infectious Bursal disease, Live
28. Infectious Avian Encephalomyelitis Vaccine, Live
29. Infectious Bursal Disease Vaccine, Inactivated
30. Infectious Chicken Anaemia, Live
31. Infectious Canine Hepatitis Vaccine, Inactivated
32. Infectious Chicken Anaemia Vaccine, Inactivated
33. Peste Des Petits Ruminants Vaccine, Live
34. Infectious Coryza Vaccine, Inactivated
35. Marek's Disease Vaccine, Live
36. Ranikhet Disease Vaccine, Live (Lentogenic Strain)
37. Rabies Veterinary Vaccine, Inactivated (Cell Culture)
38. Ranikhet Disease Vaccine, Inactivated
39. Reo Virus Vaccine, Live
40. Ranikhet Disease Vaccine, Live (Mesogenic Strain)
41. Reo Virus Vaccine, Inactivated
42. Sheep Pox Vaccine, Live
43. Salmonella Abortus Equi Vaccine, Inactivated
44. Salmonella Vaccine, Inactivated
45. Tetanus Veterinary Vaccine
46. Theileriosis Vaccine, Live

Omissions

- | | | | |
|---|---|---|---|
| 1 | Multicomponent Clostridium Vaccine | 2 | Clostridium Novyi (Type B) Vaccine for Veterinary Use |
| 3 | Clostridium Septicum Vaccine, Inactivated | 4 | Haemorrhagic Septicaemia Vaccine - Alum Treated |
| 5 | Platelet Concentrate | | |

Change of Titles

General Chapters

- 2.1.7. Weights and Balances changed to 2.1.7. Balances used in Analytical Procedures
- 2.5.3. Uniformity of Weight of Single Dose Preparation changed to 2.5.3. Weight Variation
- 2.5.4. Uniformity of Content of Single Dose Preparation changed to 2.5.4. Uniformity of Dosage Units

Monographs

- | | | | |
|-----|--|-----|--|
| 1. | Aciclovir Intravenous Infusion changed to Aciclovir for Intravenous Infusion | 2. | Amoxycillin Injection changed to Amoxycillin for Injection |
| 3. | Amoxycillin Oral Suspension changed to Amoxycillin for Oral Suspension | 4. | Amoxycillin and Potassium Clavulanate Injection changed to Amoxycillin and Potassium Clavulanate for Injection |
| 5. | Amoxycillin and Potassium Clavulanate Oral Suspension changed to Amoxycillin and Potassium Clavulanate for Oral Suspension | 6. | Amphotericin B Injection changed to Amphotericin B for Injection |
| 7. | Ampicillin Injection changed to Ampicillin for Injection | 8. | Ampicillin Oral Suspension changed to Ampicillin for Oral Suspension |
| 9. | Artesunate Injection changed to Artesunate for Injection | 10. | Azithromycin Oral Suspension changed to Azithromycin for Oral Suspension |
| 11. | Bendamustine Injection changed to Bendamustine for Injection | 12. | Benzathine Penicillin Injection changed to Benzathine Penicillin for Injection |
| 13. | Fortified Benzathine Penicillin Injection changed to Fortified | 14. | Benzathine Penicillin for Injection Benzylpenicillin Injection changed to Benzylpenicillin for Injection |
| 15. | Bleomycin Injection changed to Bleomycin for Injection | 16. | Bortezomib Injection changed to Bortezomib for Injection |
| 17. | Capreomycin Injection changed to Capreomycin for Injection | 18. | Carbenicillin Sodium Injection changed to Carbenicillin Sodium for Injection |
| 19. | Carmustine Injection changed to Carmustine for Injection | 20. | Cefaclor Oral Suspension changed to Cefaclor for Oral Suspension |

- | | |
|--|--|
| 21. Cefadroxil Oral Suspension changed to Cefadroxil for Oral Suspension | 22. Cefamandole Injection changed to Cefamandole for Injection |
| 23. Cefazolin Sodium Injection changed to Cefazolin Sodium for Injection | 24. Cefdinir Oral Suspension changed to Cefdinir for Oral Suspension |
| 25. Cefepime Injection changed to Cefepime for Injection | 26. Cefixime Oral Suspension changed to Cefixime for Oral Suspension |
| 27. Cefoperazone Injection changed to Cefoperazone for Injection | 28. Cefoperazone Sodium Injection changed to Cefoperazone Sodium for Injection |
| 29. Cefotaxime Sodium Injection changed to Cefotaxime Sodium for Injection | 30. Cefpirome Injection changed to Cefpirome for Injection |
| 31. Cefpodoxime Oral Suspension changed to Cefpodoxime for Oral Suspension | 32. Ceftriaxone Injection changed to Ceftriaxone for Injection |
| 33. Cefuroxime Injection changed to Cefuroxime for Injection | 34. Cephalexin Oral Suspension changed to Cephalexin for Oral Suspension |
| 35. Cephaloridine Injection changed to Cephaloridine for Injection | 36. Chloramphenicol Sodium Succinate Injection changed to Chloramphenicol Sodium Succinate for Injection |
| 37. Chlorothiazide Oral Suspension changed to Chlorothiazide for Oral Suspension | 38. Chorionic Gonadotrophin Injection changed to Chorionic Gonadotrophin for Injection |
| 39. Clindamycin Palmitate Hydrochloride Oral Solution changed to Clindamycin Palmitate Hydrochloride for Oral Solution | 40. Cloxacillin Injection changed to Cloxacillin for Injection |
| 41. Cloxacillin Syrup changed to Cloxacillin for Oral Solution | 42. Colistimethate Injection changed to Colistimethate for Injection |
| 43. Colistin Sulphate Oral Suspension changed to Colistin Sulphate for Oral Suspension | 44. Cyclophosphamide Injection changed to Cyclophosphamide for Injection |
| 45. Cytarabine Injection changed to Cytarabine for Injection | 46. Dacarbazine Injection changed to Dacarbazine for Injection |
| 47. Daunorubicin Injection changed to Daunorubicin for Injection | 48. Desferrioxamine Injection changed to Desferrioxamine for Injection |
| 49. Dexchlorpheniramine Oral Solution changed to Dexchlorpheniramine for Oral Solution | 50. Dicloxacillin Oral Suspension changed to Dicloxacillin for Oral Suspension |
| 51. Flucloxacillin Oral Solution changed to Flucloxacillin for Oral Solution | 52. Fluconazole Oral Suspension changed to Fluconazole for Oral Suspension |
| 53. Flucytosine Oral Suspension changed to Flucytosine for Oral Suspension | 54. Ganciclovir Injection changed to Ganciclovir for Injection |

- | | |
|--|--|
| 55. Ganciclovir Oral Suspension changed to Ganciclovir for Oral Suspension | 56. Gemcitabine Injection changed to Gemcitabine for Injection |
| 57. Hyaluronidase Injection changed to Hyaluronidase for Injection | 58. Hydralazine Injection changed to Hydralazine for Injection |
| 59. Hydrocortisone Sodium Succinate Injection changed to Hydrocortisone Sodium Succinate for Injection | 60. Hyoscyamine Oral Solution changed to Hyoscyamine for Oral Solution |
| 61. Ifosfamide Injection changed to Ifosfamide for Injection | 62. Imipenem and Cilastatin Injection changed to Imipenem and Cilastatin for Injection |
| 63. Melphalan Injection changed to Melphalan for Injection | 64. Meropenem Injection changed to Meropenem for Injection |
| 65. Mitomycin Injection changed to Mitomycin for Injection | 66. Mustine Injection changed to Mustine for Injection |
| 67. Mycophenolate Mofetil Oral Suspension changed to | 68. Mycophenolate Mofetil for Oral Suspension |
| 69. Oseltamivir Oral Suspension changed to Oseltamivir for Oral Suspension | 70. Oxytetracycline Hydrochloride Injection changed to |
| 71. Oxytetracycline Hydrochloride for Injection | 72. Pamidronate Disodium Injection changed to Pamidronate Disodium for Injection |
| 73. Pemetrexed Injection changed to Pemetrexed for Injection | 74. Pentamidine Injection changed to Pentamidine for Injection |
| 75. Phenytoin Injection changed to Phenytoin for Injection | 76. Piperacillin and Tazobactam Injection changed to Piperacillin and Tazobactam for Injection |
| 77. Piperacillin Intravenous Infusion changed to Piperacillin for Intravenous Infusion | 78. Pralidoxime Chloride Injection changed to Pralidoxime Chloride for Injection |
| 79. Fortified Procaine Penicillin Injection changed to Fortified Procaine Penicillin for Injection | 80. Rabeprazole Injection changed to Rabeprazole for Injection |
| 81. Remdesivir Injection changed to Remdesivir for Injection | 82. Sodium Nitroprusside Injection changed to Sodium Nitroprusside for Injection |
| 83. Stavudine Oral Solution changed to Stavudine for Oral Solution | 84. Streptokinase Injection changed to Streptokinase for Injection |
| 85. Streptomycin Injection changed to Streptomycin for Injection | 86. Teicoplanin Injection changed to Teicoplanin for Injection |
| 87. Temozolomide Injection changed to Temozolomide for Injection | 88. Thiopentone Injection changed to Thiopentone for Injection |
| 89. Thiotepa Injection changed to Thiotepa for Injection | 90. Tigecycline Injection changed to Tigecycline for Injection |
| 91. Vancomycin Intravenous Infusion changed to Vancomycin for Intravenous Infusion | 92. Vecuronium Bromide Injection changed to Vecuronium Bromide for Injection |
| 93. Vinblastine Injection changed to Vinblastine for Injection | 94. Vincristine Injection changed to Vincristine for Injection |
| 95. Voriconazole Injection changed to Voriconazole for Injection | 96. Zoledronic Acid Injection changed to Zoledronic Acid for Injection |

Blood and Blood Related Products

1. Concentrated Human Red Blood Corpuscles changed to Packed Red Blood Cells
2. Whole Human Blood changed to Whole Blood

Veterinary Monographs

1. Avian Spirochaetosis Vaccine changed to Avian Spirochaetosis Vaccine, Inactivated
2. Infectious coryza vaccine changed to Infectious coryza vaccine, inactivated
3. Salmonella Abortus Equi Vaccine changed to Salmonella Abortus Equi Vaccine, Inactivated
4. Sheep Pox Vaccine, Live Attenuated changed to Sheep Pox Vaccine Live

Monographs shifted from Vitamins, Minerals, Amino Acids, Fatty Acids etc. to Monographs on Drug substances, Dosage forms and Pharmaceutical aids (A to Z)

- | | | | |
|--------------------------------|-----------------------------|---|--|
| 1. Alfacalcidol | 2. Arginine | 3. Ascorbic Acid | 4. Biotin |
| 5. Calcipotriol Anhydrous | 6. Calcitriol | 7. Calcium Carbonate | 8. Calcium Chloride |
| 9. Calcium Citrate Malate | 10. Calcium Folate | 11. Calcium Gluconate | 12. Calcium Lactate |
| 13. Calcium Levulinate | 14. Calcium Pantothenate | 15. Dibasic Calcium Phosphate, Anhydrous | 16. Dibasic Calcium Phosphate, Dihydrate |
| 17. Tribasic Calcium Phosphate | 18. Cholecalciferol | 19. Cholecalciferol Concentrate (Powder Form) | 20. Chromium Picolinate |
| 21. Citric Acid | 22. Citric Acid Monohydrate | 23. Copper Gluconate | 24. Cyanocobalamin |
| 25. Ergocalciferol | 26. Ferrous Ascorbate | 27. Ferrous Fumarate | 28. Ferrous Gluconate |
| 29. Ferrous Sulphate | 30. Dried Ferrous Sulphate | 31. Folic Acid | 32. Glutamic Acid |
| 33. Glycine | 34. Inositol | 35. Iron and Ammonium Citrate | 36. Levocarnitine |
| 37. Alpha Lipoic Acid | 38. Lutein | 39. Lysine Hydrochloride | 40. Heavy Magnesium Carbonate |
| 41. Light Magnesium Carbonate | 42. Magnesium Chloride | 43. Heavy Magnesium Oxide | 44. Light Magnesium Oxide |
| 45. Magnesium Sulphate | 46. Magnesium Trisilicate | 47. Methylcobalamin | 48. Nicotinamide |
| 49. Nicotinic Acid | 50. D-Panthenol | 51. Pepsin | 52. Phenylalanine |

- | | | | |
|--------------------------|-------------------------------|----------------------------------|--|
| 53. Phytomenadione | 54. Potassium Chloride | 55. Potassium Citrate | 56. Potassium Iodide |
| 57. Potassium Sorbate | 58. Pyridoxine Hydrochloride | 59. Riboflavin | 60. Riboflavin Sodium Phosphate |
| 61. Selenious Acid | 62. Selenomethionine | 63. Sodium Citrate | 64. Thiamine Hydrochloride |
| 65. Thiamine Mononitrate | 66. Threonine | 67. Tocopheryl Acetate | 68. Tryptophan |
| 69. Valine | 70. Vitamin A Concentrate Oil | 71. Vitamin A Concentrate Powder | 72. Water-Miscible Vitamin A Concentrate |
| 73. Zinc Chloride | 74. Zinc Citrate | 75. Zinc Sulphate | 76. Zinc Sulphate Monohydrate |

International Recognition of the IP

India and the Republic of Trinidad and Tobago

India and the Republic of Trinidad and Tobago signed an MoU recognizing the Indian Pharmacopoeia (IP) for the quality standards of medicines.

This MoU was signed on 04 July 2025, during the visit of Hon'ble Prime Minister Shri Narendra Modi to Trinidad and Tobago, marking an important step in pharmacopoeial cooperation and paving the way for closer collaboration in the pharmaceutical sector.



India and the Maldives

India and the Maldives also signed an MoU recognizing the IP.

The MoU was exchanged on 25th July 2025 between the Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of India, and the Maldives Food and Drug Authority (MFDA), Ministry of Health, Republic of Maldives, in the esteemed presence of Shri Narendra Modi, Hon'ble



Prime Minister of India, and His Excellency Dr. Mohamed Muizzu, President of the Republic of Maldives.

India and the Republic of Botswana

India and the Republic of Botswana signed an MoU for the recognition of IP, marking an important milestone in improving the accessibility of quality-assured medicines in Botswana.

The agreement was signed in the esteemed presence of Smt. Droupadi Murmu, Hon'ble President of India, and His Excellency Advocate Duma Gideon Boko, President of the Republic of Botswana, on 12th November 2025.



India and Liberia

India and Liberia signed an MoU on 11th December 2025 to strengthen cooperation in the field of pharmacopoeia. The MoU was formally signed today at the Ministry of Health of Liberia by H.E. Mr. Manoj Bihari Verma, Ambassador of India to Liberia, on behalf of the Indian Pharmacopoeia Commission; and H.E. Dr. Louise M. Kpoto, Minister of Health of Liberia.



Development of Indian Pharmacopoeia Reference Standards (IPRS)

New IPRS Developed

- Hydrocortisone (Cortisone)

New Impurities Developed

- Gemcitabine Impurity A
- Diphenhydramine Impurity E
- Ketorolac Impurity A
- Ropinirole Impurity B

Particulars	Numbers
No. of new IPRS developed	01
No. of new Impurities (IMP-RS) developed	04
No. of IPRS lot changed	43
No of IMP-RS Lot Change	23
Current availability of IPRS	691
Current availability of IMP-RS	635

Testing of Samples

Type of samples	No. of samples tested
No. of New Drugs Substances Tested	195
No. of Misc./CMSS & Port Tested	494
No. of Cough Syrup Tested	198

National Collaborations

MoU Signed Between IPC and Uttar Pradesh Pharmacy Council (UPPC)

An MoU was signed between the Indian Pharmacopoeia Commission and the Uttar Pradesh Pharmacy Council (UPPC) at the UPPC office in Lucknow on 24th September 2025 to promote the rational use of medicines through the National Formulary of India (NFI).



Under this initiative, UPPC will make it mandatory for all registered pharmacists in the state to subscribe to the NFI,

ensuring its wider adoption at the grassroots level. With this collaboration, UPPC became the first State Pharmacy Council in the country to partner with IPC in the larger interest of patient safety.

MoU Signed Between IPC and Tamil Nadu State Pharmacy Council

IPC also signed an MoU with the Tamil Nadu State Pharmacy Council (TNPC) on 09th November 2025 to promote the safe and rational use of medicines through collaborative efforts in pharmacovigilance, patient safety, and professional awareness among pharmacists.



Under this partnership, both organisations will work together to strengthen the role of registered pharmacists in adverse drug

reaction (ADR) reporting, enhance medicine and device safety through PvPI and MvPI, and promote wider adoption of the National Formulary of India (NFI) across healthcare institutions in Tamil Nadu.

MoU Signed Between IPC and Jharkhand State Pharmacy Council (JSPC)

IPC signed an MoU with the Jharkhand State Pharmacy Council (JSPC) on 15th November 2025 to strengthen collaborative efforts aimed at promoting the safe and rational use of medicines, enhancing pharmacovigilance and materiovigilance activities, and advancing patient safety initiatives across the state of Jharkhand.

The MoU was signed by Dr. Vivekanandan Kalaiselvan, Secretary-cum-Scientific Director,

IPC, and Shri Prasanth Kumar Pandey, Registrar-cum-Secretary, JSPC, in the presence of representatives from both organisations.



IPC Signs Three MoUs in Nagaland to Strengthen Medicine and Patient Safety Ecosystem

IPC signed three MoUs with the Nagaland Medical Council, Nagaland State Drugs Control Administration (NSDCA), and the Nagaland State Pharmacy Council to advance medicine safety, regulatory strengthening, and patient safety initiatives across the state. The MoUs were signed during the One-Day Training Programme held in Kohima. This collaboration focuses on enhancing pharmacovigilance and materiovigilance, promoting adverse event reporting, building stakeholder capacity, expanding ADR Monitoring Centres (AMCs) and Medical Device Monitoring Centres (MDMCs), and strengthening the adoption of the National Formulary of India (NFI) across healthcare facilities.



Notably, the MoU with the Nagaland Medical Council marks the first-ever agreement with any State Medical Council in India to promote PvPI and MvPI up to the level of Primary Health Centres. The MoU with NSDCA is IPC's second of its kind after UPFDA and the first in the North Eastern region. The agreement with the Nagaland State Pharmacy Council becomes the fourth such partnership in India to advance safe and rational medicine use.

International Engagements

Sixth Meeting of Assembly of South-East Asia Regulatory Network (SEARN) commences in Thimphu, Bhutan

Dr. Vivekanandan Kalaiselvan, Secretary-cum-Scientific Director, Indian Pharmacopoeia Commission (IPC) attended the Meeting of the Assembly of South-East Asia Regulatory Network (SEARN) officially commenced in Thimphu, Bhutan on 15th July 2025. The two-day meeting was hosted by the Bhutan Food and Drug Authority (BFDA), Ministry of Health, with the support of the World Health Organization (WHO). This high-level event brought together regulatory leaders and stakeholders from across the South-East Asia Region to advance regulatory collaboration, convergence and reliance across the region.



PDG Annual Meeting 2025

Dr. Gaurav Pratap Singh, Senior Principal Scientific Officer, Ms. Anubhuti Goyal, Scientific Assistant, and Sh. Muneer Javed Mohammed, Scientific Assistant, from IPC, attended the 'PDG Annual Meeting 2025' at Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan, from 30th September to 1st October, 2025. A brief presentation on IPC updates was given, wherein salient features of the IP 2026, general chapter revisions, establishment of IPRS, features of the IP Online Portal, and progress on PDG harmonization were briefed to the PDG. IPC will be the host pharmacopoeia for the next one-year cycle, and the next PDG Annual Meeting 2026 will be organised by the IPC.



Meeting with the Ethiopian delegation

IPC hosted the Ethiopian delegation on 14th November 2025 for an insightful exchange on the Indian Pharmacopoeia, discussing opportunities for harmonization, knowledge-sharing, and strengthening regulatory collaboration. The visit opened meaningful possibilities for future partnership and expansion to support quality standards in public health.



Meeting with Myanmar Authorities

IPC engaged with Myanmar authorities, as well as the pharmaceutical industry and the FDA, to advance dialogue on regulatory convergence and medicine quality from 8th-9th December 2025.

IPC offered its support to Myanmar in strengthening capacity building in drug testing and pharmacovigilance, underscoring a shared commitment to medicine quality and patient safety. Representatives of the Central Drugs Standard Control Organization (CDSCO), Government of India, were also part of the engagements.



Nepal Delegation Visit to IPC

IPC hosted a high-level delegation from Nepal at its headquarters in Ghaziabad on 17th December 2025. The Nepalese delegation was led by Hon'ble Dr. Sudha Sharma Gautam, Minister of Health and Population, Government of Nepal, and included senior officials from the Ministry of Health and Population, Government of Nepal, along with representatives from the Embassy of Nepal in New Delhi.



The visit aimed to strengthen bilateral cooperation in pharmaceutical regulation, drug standards, and quality assurance. Discussions were held in line with the agreed agenda and focused on regulatory systems, institutional mechanisms, and opportunities for technical collaboration.

Seychelles Delegation Visit to IPC

IPC hosted a high-level delegation from Seychelles on 17th December 2025 at its headquarters in Ghaziabad. The delegation was led by Dr Marvin Nolan Fanny, Hon'ble Minister of Health of the Republic of Seychelles, and was accompanied by Ms Leon Lindy and Ms Corrine Evenor.

The visit provided an opportunity to strengthen bilateral engagement in the areas of pharmaceutical regulation, drug standards, and quality assurance.



Trinidad and Tobago Delegation Visit to IPC

IPC hosted a high-level delegation from Trinidad and Tobago at its headquarters in Ghaziabad on 18th December 2025. The delegation was led by The Honourable Dr Rishad Seecheran, Minister in the Ministry of Health, Government of Trinidad and Tobago, and included Mrs Anessa Doodnath-Siboo, Principal Pharmacist, Ministry of Health and His Excellency Mr Chandradath Singh, High Commissioner-designate for the Republic of Trinidad and Tobago to India.



The visit aimed to strengthen bilateral cooperation in pharmaceutical regulation, drug standards, and quality assurance. Discussions were held in line with the agreed agenda, with a focus on regulatory frameworks and institutional systems. The visit concluded with a facility tour of IPC.

Interactives Meets & In-house Training Activities

IPEC India Annual Conference 2025

Dr. Gaurav Pratap Singh Jadaun, Senior Principal Scientific Officer, participated in the IPEC India Annual Conference 2025, held in Mumbai on 25th July 2025, and took part in a panel discussion on “Evolving Trends in Quality and Regulatory.”



Academic Interaction Meeting in the Presence of Hon'ble Vice-Chancellor, DPSRU

An interactive session with Deans, Principals, and Heads of Departments of pharmacy institutions, held in the presence of the Hon'ble Vice-Chancellor, DPSRU, on 4th August 2025.



Two-day workshop on “Enhancing Pharmacopoeial Standards and Safety Reliance through Scientific Publications”

The Indian Pharmacopoeia Commission (IPC) recently hosted a two-day workshop on “Enhancing Pharmacopoeial Standards and Safety Reliance through Scientific Publications” at its headquarters in Ghaziabad on 28th - 29th August 2025.

The workshop brought together experts from AIIMS, PGIMER, NIPER, DPSRU, and NITI Aayog, who shared insights on evolving pharmacopoeial standards, impurity documentation, legal and ethical dimensions of publishing, editors' perspectives on acceptance and review, and strategies for avoiding predatory journals. Expert talks were complemented with interactive group exercises, making the experience both insightful and engaging. Participants from regulatory bodies, academia, and research organisations came together to learn, collaborate, and share ideas for strengthening scientific contributions and ensuring drug safety.



Meeting on “Promoting the Quality, Safety and Rational Use of Anti-TB Drugs”

The Indian Pharmacopoeia Commission (IPC) successfully organized a meeting on “Promoting the Quality, Safety and Rational Use of Anti-TB Drugs – Current Status and Way Forward in TB Elimination” on 30th October 2025 at IPC, Ghaziabad, in hybrid mode.

The meeting was graced and chaired by Dr. Soumya Swaminathan, Ex-Chief Scientist, World Health Organization, Geneva & Ex-Director General, Indian Council of Medical Research (ICMR), New Delhi. IPC was deeply honoured to have her distinguished presence and guidance.



Dr. Swaminathan's insightful address emphasized the importance of ensuring the quality, safety, and rational use of anti-TB medicines. She emphasized the need to develop monographs for new anti-TB drugs to be included in the Indian Pharmacopoeia (IP) and advised exploring the integration of Ni-kshay and ADRMS platforms to enable efficient collection and analysis of Adverse Drug Reaction (ADR) data related to anti-TB medicines.

The deliberations brought together experts and representatives from NITI Aayog, NTEP, Indian Council of Medical Research (ICMR)& ICMR-NIRT, Central Drugs Standard Control Organization, WHO Country Office for India, and Translational Health Science and Technology Institute (THSTI), who shared valuable perspectives on standards development, safety surveillance, and digital tools for medicine monitoring.



IPC at the 22nd Indo-US Economic Summit 2025

IPC participated in the 22nd Indo-US Economic Summit 2025 on 18th November 2025, showcasing India's growing leadership in global standards, regulatory harmonisation, and public health collaboration. Hon'ble Minister Shri Piyush Goyal, Minister of Commerce & Industry, Government of India, graced the 22nd Indo-US Economic Summit as the Chief Guest. At the summit themed "Shaping a Shared Future: India-US Collaboration for Global Resilience", IPC highlighted India's growing role in global standards and regulatory cooperation. The Secretary-cum-Scientific Director of IPC, Dr. Vivekanandan Kalaiselvan, spoke on the 'Indo-US Partnership in Healthcare Sector'. He shared updates on the Indian Pharmacopoeia, progress in monograph development, and the strengthening IPC-USP partnership focused on collaboration and harmonisation.



The session also spotlighted ongoing cooperation between PvPI (IPC) and USFDA for pharmacopoeia-oriented training and capacity building, reinforcing shared goals of medicine safety, regulatory strengthening, and global public health.

IPC–DAVV Conference Strengthens India's Commitment to Drug Quality and Patient Safety

A one-day national conference jointly organised by the Indian Pharmacopoeia Commission (IPC) and the Pharmacy Study Centre of Devi Ahilya Vishwavidyalaya (DAVV), Indore, successfully concluded in Indore, bringing together regulators, industry leaders, academic experts, and students for an in-depth discussion on drug quality, patient safety, and national regulatory standards.

Dr. Vivekanandan Kalaiselvan, Secretary-cum-Scientific Director, IPC, highlighted the critical role of pharmacopoeial standards in ensuring the quality of medicines manufactured and consumed in the country. He also emphasised IPC's contributions to the Indian Pharmacopoeia and its leadership of the Pharmacovigilance Programme of India. The conference strengthened engagement between academia, industry, and regulatory bodies, advancing collective efforts to enhance drug quality, patient safety, and national health systems.



IPC Hosts Interactive Meet on Pharmacopoeia Standards in Chennai

The Indian Pharmacopoeia Commission (IPC), Ghaziabad, in association with the Indian Drug Manufacturers Association (Tamil Nadu, Puducherry & Kerala Board), organised the “IPC Interactive Meet on Pharmacopoeia Standards: Regulatory and Quality Considerations” in Chennai on 8th November 2025.

The programme witnessed active participation from around 100 delegates representing pharmaceutical industries across the region. The discussions focused on strengthening understanding of pharmacopoeial standards, aligning regulatory expectations, and enhancing quality practices in drug manufacturing.



Dr. Vivekanandan Kalaiselvan, Secretary-cum-Scientific Director, IPC, delivered the keynote address on the role of IPC in ensuring medicine quality and patient safety, highlighting ongoing initiatives in strengthening pharmacopoeial standards. Dr. Gaurav Pratap Singh Jadaun, Senior Principal Scientific Officer, presented updates on Indian Pharmacopoeia standards with a focus on digital solutions, global footprints, and evolving regulatory expectations. Dr. Manisha Trivedi, Scientific Officer, provided insights into Indian Pharmacopoeia Reference Standards and their critical role in maintaining the accuracy, reliability, and consistency of quality testing in pharmaceutical manufacturing.



Hands-on Training on Ethylene Glycol (EG) and Diethylene Glycol (DEG)

Indian Pharmacopoeia Commission (IPC) successfully organized the 1st Hands-on Training on Ethylene Glycol (EG) and Diethylene Glycol (DEG) Determination in Oral Liquid Preparations by Gas Chromatography (GC) from 11th to 13th November 2025.

The three-day training brought together 25 participants from 10 states, (Himachal Pradesh, Hyderabad, Jammu & Kashmir, Madhya Pradesh, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh, Uttarakhand) providing them with practical exposure to method development, sample analysis, and chromatogram interpretation using GC.

In light of Amendment List 09 to IP-2022, effective from 10th October 2025, which mandates DEG and EG testing in all oral liquid formulations, IPC continues to strengthen analytical capacity through such specialized programmes. Participants also gained insights into the possible sources of DEG/EG contamination and the importance of ensuring the safety and quality of pharmaceutical products.



13th Annual National Conference of the Indian Society of Transfusion Medicine – TRANSMEDCON 2025

IPC participated in the 13th Annual National Conference of the Indian Society of Transfusion Medicine – TRANSMEDCON 2025, held at the Rajasthan International Centre, Jaipur (28th - 30th November 2025).

A talk was delivered on “Initiatives of the Indian Pharmacopoeia Commission (IPC) for Blood Component's Quality” in the high-impact session “National Blood Policy and Programmes – Achievements and Future Plans.



This conference served as an inspiring platform that brought together national experts, policymakers, and scientific leaders dedicated to advancing transfusion medicine in India.

13th Annual International Symposium on Dissolution Science and Applications – Disso India

Dr. Vivekanandan Kalaiselvan, Secretary-cum-Scientific Director, Indian Pharmacopoeia Commission (IPC), delivered the Chief Guest Address at the 13th Annual International Symposium on Dissolution Science and Applications – Disso India, held at SVKM's NarseeMonjee Institute of Management Studies (NMIMS), Mumbai, on November 21st-22nd, 2025.

His address highlighted the growing importance of dissolution science in ensuring drug quality, regulatory alignment, and patient safety, while also emphasizing IPC's ongoing efforts to strengthen pharmacopoeial standards and support innovation across the pharmaceutical sector.



IPC Represents India at International Conference on Advancing Non-Animal Testing Methods

Dr. M. Kalaivani and Dr Meenakshi Dahiya, Principal Scientific Officers from the Indian Pharmacopoeia Commission (IPC), participated in the international conference “Animal Testing Replacement for Vaccines – A One Health View: Global Outlook and Future Strategy” held in Bangkok, Thailand, from 2nd - 4th December 2025.

The event was organised by Animal-Free Safety Assessment (AFSA) and co-organised by Humane

World for Animals and IABS. During the panel discussions, Dr. Kalaivani presented “Indian Pharmacopoeia perspectives on alternatives to animal methods in the testing of vaccines for human and animal use”. She also contributed to the workshop on sustainable endotoxin testing with a talk on “Bacterial Endotoxin Test — Indian Pharmacopoeia Perspectives” under the theme Sustainable Endotoxin Testing: Developing a Roadmap for LMIC Implementation.

The event included participation from regulatory and scientific experts representing World Health Organization, World Organisation for Animal Health, Medicines and Healthcare products Regulatory Agency, NIH (USA), European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, Health Canada | Santé Canada, BADAN POM Indonesia, National Veterinary Assay Laboratory Japan, ICAR-NI-FMD India, CEPI, PATH, vaccine manufacturers, and industry partners.



Scientific talk on “New Drug Discovery and Development Against Tuberculosis”

IPC organised a scientific talk titled “*New Drug Discovery and Development Against Tuberculosis: Challenges and Opportunities*” on 3rd December 2025 at IPC. The session highlighted current scientific advances, key challenges, and emerging opportunities in tuberculosis drug discovery and development, fostering knowledge exchange among researchers and professionals.



74th Indian Pharmaceutical Congress

Dr. Gaurav Pratap Singh Jadaun, Senior Principal Scientific Officer, participated in the Presidential Panel Discussion during the 74th Indian Pharmaceutical Congress, held on 19th December 2025 in Bengaluru, on the theme “Viksit Bharat 2047: India's potential in shaping the future of global pharma and healthcare, role of academia, industry, and regulatory agencies.



Other Significant Activities

Rashtriya Karmayogi Large-Scale Jan Seva Programme

Participation in Rashtriya Karmayogi Large-Scale Jan Seva Programme – Phase II (RKLSJSP-II) Officials from the Microbiology Division attended the Rashtriya Karmayogi Large-Scale Jan Seva Programme – Phase II (RKLSJSP-II) Master Training Programme held from 8th -10th October 2025 at the National Institute of Health and Family Welfare, New Delhi.

Subsequently, the programme was conducted at the Indian Pharmacopoeia Commission, Ghaziabad, on 14th and 17th November 2025 by the Capacity Building Commission, with Illumine Knowledge Resources as the Knowledge Partner. The initiative aimed at strengthening citizen-centric service delivery, enhancing professional competence, and reinforcing public service values among officials.



Swasth Nari Sashakt Parivar Abhiyaan (SNSPA)

IPC successfully undertook a series of awareness and engagement activities in alignment with the Swasth Nari Sashakt Parivar Abhiyaan (SNSPA), a national initiative of the Ministry of Health and Family Welfare and the Ministry of Women and Child Development.

These activities reflected IPC's commitment to promoting women's health, well-being, and informed healthcare practices within the workplace. Women employees actively participated in programmes such

as yoga sessions, health camps, and lectures on women-centric issues, underscoring the importance of institutional initiatives that encourage health awareness, preventive care, and balance in professional life.



SNSPA, conceptualised as a Jan Bhagidaari Abhiyaan, aims to strengthen healthcare services for women and children across India by improving access, quality of care, and awareness. The initiative also promotes collective participation from public and private healthcare institutions, professionals, and communities to ensure inclusive and people-centric healthcare delivery.

The nationwide campaign was inaugurated on 17th September 2025 by the Hon'ble Prime Minister Narendra Modi, coinciding with his 75th birthday and reinforcing the national vision of empowered women, healthy families, and resilient communities.



Hindi Pakhwada

Hindi Pakhwada was observed at IPC from 14th - 28th September 2025, in line with the Government of India's initiatives to promote the use of Hindi in official work.

During the fortnight, various activities were organised to encourage progressive use of Hindi and strengthen linguistic awareness among officials.



Webinars by the Indian Pharmacopoeia Commission (IPC)

As part of its continued efforts to strengthen awareness, capacity building, and stakeholder engagement, IPC organised a series of national webinars. These sessions focused on pharmacopoeial access, updates, quality standards, and scholarly capacity building.

Highlights of IPC Webinars

- 01** Discover & Unlock Access to Indian Pharmacopoeia via IP Online Portal, 28 July 2025: An orientation webinar guiding stakeholders on seamless digital access to IP standards through the IP Online Portal.
- 02** Updates of Indian Pharmacopoeia (IP) and IP Reference Substances (IPRS), 25 August 2025: A technical update session covering recent revisions, additions, and developments in IP and IPRS.
- 03** Webinar on Pharmacopoeia and regulatory updates to address DEG and EG contamination, October 13, 2025: A focused technical webinar highlighting pharmacopoeial provisions, regulatory measures, and best practices to prevent and address diethylene glycol (DEG) and ethylene glycol (EG) contamination in pharmaceutical products.
- 04** National Webinar on Blood and Blood Components: Ensuring Quality and Safety through Indian Pharmacopoeia, 7 November 2025: A focused discussion on quality assurance and safety standards for blood and blood components as per IP provisions..
- 05** Authors' Workshop organised by ASCE under the ONOS Outreach Programme, 12 December 2025 A scholarly capacity-building webinar aimed at improving scientific writing and publication skills among researchers.



INDIAN PHARMACOPOEIA COMMISSION

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

Sector-23, Raj Nagar, Ghaziabad

Uttar Pradesh (India)

Tel.: 0120-2783392, 2783400 Mob.: +91-9654631395

Email: lab.ipc@gov.in Website: www.ipc.gov.in

PURCHASE



IP ONLINE



IPRS STORE